BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)

Core Insights - TG Therapeutics Inc. (NASDAQ:TGTX) is recognized as one of the 10 most shorted biotech stocks to buy according to hedge funds [1] - The company reported Q4 revenue of $192.6 million, slightly below consensus estimates of $193.3 million [1] - CEO Michael Weiss highlighted 2025 as a promising year for TG Therapeutics, particularly due to the momentum surrounding BRIUMVI [1] Financial Performance - The company experienced significant year-over-year growth both in the U.S. and globally, attributed to increased adoption and availability of its products [2] - TG Therapeutics is advancing its late-stage clinical programs and strengthening its financial foundation as it approaches 2026 [2] - The company is focused on delivering value to patients, healthcare providers, and shareholders through disciplined business operations and good financial guidance [2] Product Development - BRIUMVI is a key product for TG Therapeutics, aimed at transforming the treatment landscape for B-cell mediated diseases, including multiple sclerosis [5][6] - The company specializes in acquiring, developing, and commercializing innovative therapies to improve patient outcomes and quality of life [5][6] Analyst Insights - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while maintaining an Overweight rating, indicating an upside potential of over 57% [4]